- Peck currently is Executive Vice President & Group
President responsible for U.S. Operations, Business Development and
Strategy
- Alaix to retire as CEO effective December 31, 2019, and will
act as advisor on leadership transition through December 31,
2020
Zoetis Inc. (NYSE: ZTS) today announced that Kristin Peck will
succeed Juan Ramón Alaix as Chief Executive Officer, effective
January 1, 2020, and join the Board of Directors, effective
immediately. Alaix, who has been CEO of Zoetis since its formation
in 2012, has decided to retire as CEO effective December 31, 2019.
He will act as an advisor on the leadership transition through
December 31, 2020.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191003005420/en/
Kristin Peck will succeed Juan Ramón
Alaix as Chief Executive Officer of Zoetis, effective January 1,
2020, and join the Board of Directors, effective immediately.
(Photo: Zoetis)
Peck currently serves as Executive Vice President and Group
President of U.S. Operations, Business Development and Strategy,
and she has been a member of the Zoetis executive leadership team
since the company’s formation in 2012. She will remain in her
current position until the transition is complete on December 31,
2019.
“Kristin is the right leader for Zoetis’ future,” said Alaix.
“She is an advocate for our customers’ needs, a champion of Zoetis’
culture and values, and an inspirational and collaborative leader
for our people and industry. Her strategic vision and proven track
record of performance throughout her tenure at the company, as well
as her operational experience and deep customer knowledge, have her
well-prepared to drive Zoetis’ continued growth for the benefit of
all our key stakeholders.”
“Kristin has been an integral part of the management team that
has firmly established Zoetis as the world leader in animal
health,” said Michael McCallister, Chairman of the Board of
Directors of Zoetis. “As head of U.S. Operations, she has been an
innovator around customer experience, creating new customer loyalty
programs and investing in digital tools, campaigns and
direct-to-consumer advertising to support our growth. She has a
disciplined growth mindset when it comes to leading our business
development and strategy functions, and, earlier in her tenure, she
helped drive improvements in manufacturing and supply chain to make
them more efficient. Kristin has the passion, talent and experience
necessary to lead Zoetis in the next stage of its journey.”
“Zoetis plays an essential role in caring for the pets and
livestock that enrich people’s lives, and I am grateful for the
opportunity to lead our company as the next CEO. I look forward to
working with the Board, Juan Ramón and the Zoetis executive team on
this transition,” said Peck. “We will continue to serve our
customers, colleagues, shareholders and society by advancing animal
health, and we will remain committed to building on the strategies,
diverse portfolio, talented people and financial discipline that
have been critical to our success.”
Leadership and Stewardship of First CEO
“We want to thank Juan Ramón for his leadership and stewardship
as the first CEO of Zoetis,” continued McCallister. “During his
tenure, he drove innovation and consistently delivered strong
financial results, while creating value for our customers,
shareholders and colleagues. The Board and I are grateful to Juan
Ramón for his many contributions, including his development of a
strong and talented leadership team, and we are confident Zoetis is
well-positioned for the future under Kristin.”
“Leading Zoetis has been the opportunity of a lifetime thanks to
the commitment and trust Zoetis colleagues have placed in me and
our executive team,” said Alaix. “I look forward to working with
Kristin as we complete this successful transition and prepare for
the company’s next phase of growth under her leadership.”
About Kristin Peck
Over the course of her career at Zoetis, Peck, 48, has led the
company’s Global Manufacturing and Supply organization, former
Global Poultry and Global Diagnostics businesses, and New Product
Marketing and Global Market Research. Since 2015, she has run U.S.
Operations and established a track record of consistently growing
revenue faster than the overall animal health market, while
overseeing the successful launch of new companion animal
blockbusters, such as Simparica® and Cytopoint® for dogs, as well
as the continued growth of Apoquel® into one of the largest
products in the industry. Peck has played a key role in
establishing a more data- and insight-driven sales and marketing
function for the benefit of customers in the U.S.
Since 2018, Peck has also led the company’s corporate strategy
and business development activities, including the acquisitions of
Abaxis (diagnostics) and Platinum Performance (nutritional
products) to support the continued expansion of Zoetis’
capabilities and offerings across the continuum of care.
Peck has been a passionate leader for colleague development. As
the recipient of the 2019 Feather in Her Cap Award, she was honored
for her work in mentoring women and helping them advance their
careers in animal health.
Peck previously served as Pfizer’s Executive Vice President of
Worldwide Business Development and Innovation, as part of the
company’s Executive Leadership Team. In this role, she was
responsible for the evaluation of strategic alternatives for
Pfizer's Animal Health and Nutrition businesses. Peck also has
experience working in consulting, private equity, and real estate
finance. She holds a bachelor's degree from Georgetown University
and a Master of Business Administration degree from Columbia
Business School, where she still serves as a member of the Advisory
Board for the school’s Deming Center. She has also been a member of
the Thomson Reuters' Board of Directors since 2016.
About Juan Ramón Alaix
Alaix, 68, was named CEO of Zoetis in July 2012. Under his
leadership, the company has become the global leader in animal
health, with $5.8 billion in revenue in 2018 and a market
capitalization today of nearly $60 billion. From February 1, 2013,
when Zoetis’ common shares first started trading, through September
30, 2019, the company’s cumulative total shareholder return has
been 322%, versus 126% for the S&P 500. With its steady growth
in profitability and cash flow, Zoetis has consistently increased
the value of the company by investing in commercial operations,
R&D and manufacturing, resulting in a track record of
successful new product innovation. Over his years as CEO, Alaix’s
leadership has resulted in several groundbreaking new medicines
ranked among the top products in the animal health industry.
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 65 years of experience in animal health, Zoetis discovers,
develops, manufactures and commercializes medicines, vaccines and
diagnostic products, which are complemented by biodevices, genetic
tests and a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries. In 2018, the company generated annual revenue of $5.8
billion with approximately 10,000 employees. For more information,
visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This
press release contains forward-looking statements, which reflect
the current views of Zoetis with respect to business plans or
prospects and other future events. These statements are not
guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, including in the sections thereof captioned
“Forward-Looking Statements and Factors That May Affect Future
Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on
Form 10-Q and in our Current Reports on Form 8-K. These filings and
subsequent filings are available online at www.sec.gov,
www.zoetis.com, or on request from Zoetis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191003005420/en/
Media: Bill Price 1-973-443-2742
(o) william.price@zoetis.com
Kristen Seely 1-973-443-2777 (o) kristen.seely@zoetis.com
Investors: Steve Frank
1-973-822-7141 (o) steve.frank@zoetis.com
Marissa Patel 1-973-443-2996 (o) marissa.patel@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Apr 2024 to May 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From May 2023 to May 2024